Merck & Co., Inc. (MRK) Sued By Numerous Plaintiffs Over Harm Caused By Its Zostavax Drug
Reports indicate that there are a number of plaintiffs filing lawsuits against Merck & Co., Inc.
Posts Tagged ‘Is MRK A Good Stock To Buy Right Now?’
FDA Endorses 3 New Drug Applications (NDAs) From Merck & Co., Inc. (MRK), Pfizer Inc. (PFE)
The U.S. Food and Drug Administration (FDA) has acknowledged the filing for review of three New Drug Applications (NDAs) from Merck & Co., Inc. (NYSE:MRK) and Pfizer Inc.
Merck & Co., Inc. (MRK) In $2.9 Billion Writedown After Market For Hepatitis C Drug Market Shrinks
Merck & Co., Inc. (NYSE:MRK) has announced that it will be writing down approximately $2.9 billion following the shrinking of the market for a hepatitis drug it owns.
Bristol-Myers Squibb Co (BMY), Merck & Co., Inc. (MRK), And Other Pharmaceutical Firms All Targeting I-O Segment
Reports indicate that the market for immuno-oncology drugs could grow to $25 billion in the next ten years.
The FDA Accepts Keytruda From Merck & Co., Inc. (MRK) For Bladder Cancer
Patients with bladder cancer now having something to smile about, after the acceptance of 2 new supplemental biologics license applications, by the FDA.
The European Medicines Agency (EMA) Recommends KEYTRUDA From Merck & Co., Inc. (MRK)
The European Commission has approved KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy from Merck & Co., Inc. (NYSE:MRK).
Pharmaceutical Executives From Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ) Met Trump
United States President Donald Trump is urging US drugmakers to consider manufacturing more of their drugs in the United States, thinking that higher cost manufacturing at the...
Merck & Co., Inc. (MRK) Is Among Many Drugmakers Being Criticized For Price Hikes
Merck & Co., Inc. (NYSE:MRK) is one of the pharma industry titans that are currently on the receiving end as a result of exaggerated drug price hikes.
Bristol-Myers Squibb Co (BMY) To Share In Sales Of Merck & Co., Inc. (MRK) Keytruda Following Litigation Settlement
Merck & Co., Inc. (NYSE:MRK) has agreed to share a portion of Keytruda sales with Bristol-Myers Squibb Co (NYSE:BMY) and Ono Pharmaceutical Co., Ltd.
Merck & Co., Inc. (MRK) And Palantir Technologies Inc Agree On Cancer Data Analysis Pact
Palantir Technologies Inc and Merck & Co., Inc.
Merck & Co., Inc. (MRK) Gets Coveted Approval For Keytruda
Individual lung cancer patients may soon be able to benefit from Keytruda, an immunotherapy drug from Merck & Co., Inc. (NYSE:MRK).
Here’s What The OpGen Inc (OPGN) Merck & Co., Inc. (MRK) Agreement Really Means, And Why It’s So Important
OpGen Inc (NASDAQ:OPGN), a Market Exclusive favorite, earlier this week announced that it is bolstering its already long-standing relationship with pharmaceutical giant Merck...
FDA Approves Merck & Co., Inc. (MRK) Keytruda For NSCLC
The US Food and Drug Administration (FDA) has recently approved the anti-programmed-death-receptor-1 (anti-PD-1) therapy of Merck & Co., Inc.
Merck & Co. Inc. (MRK) Shuts Down Florida Facility
The pharmaceutical giant intends to lay off employees in two waves, the first of which is set next month and the other one in December.
Inside the FDA Ebola Edition: Frontrunners Merck & Co., Inc. (MRK), GlaxoSmithKline PLC (ADR) (GSK)
Back on May 12, 2015, the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee released a briefing document detailing the process...
Market Exclusive’s Inside the FDA: This Week Bezlotoxumab from Merck & Co., Inc. (MRK)
On July 23, the Food and Drug Administration will make its decision on bezlotoxumab, brand name Zinplava, a Merck & Co., Inc.
Merck & Co., Inc. (MRK) and OpGen Inc (OPGN) Are Quietly Changing The Infectious Disease Landscape
Imagine the following scenario. A patient walks into a hospital with an infectious disease. He sees a physician or a nurse, who diagnoses him, usually on a hunch.
The Top Four Diabetes Best Sellers and One Oral Insulin Pill That May Threaten Them All
At the turn of the millennium, the population of the United States clocked in at 282.2 million.
Pfizer And Merck Earnings Previews: Mega-Cap Pharmas Try To Stem Revenue Erosion
This article is temporarily removed from Insider Monkey.
